A Look at BMY - Bristol-Myers Squibb

Updated: Aug 7, 2020

Data from sec.gov is now on emriches.com, under the "Stocks in Scope" menu.


  • Recent acquisition of Celgene added debt and shares outstanding but also increased revenues substantially

  • PE ratio misleading due to one time acquisition charges.

  • BMY has strong portfolio of drugs aimed at fighting cancer. Generally, the FDA is more likely to approve cancer drugs vs other categories.

  • BMY's Opdivo and Merck's Keytruda are the best two cancer treatments on the market. I say; own BMY, and own MRK too.

59 views0 comments